| Bioactivity | CID1231538, a benzothiazole analogue, is a potent GPR35 antagonist (IC50=0.55 μM). GPR35 is a G protein-coupled receptor (GPCR)[1]. |
| Invitro | GPR35 has gained special consideration as a result of its association with many diseases including type-2 diabetes, nociceptive pain, inflammation, mild mental retardation syndrome, metabolic disorders, and gastric cancer[1]. |
| Name | CID1231538 |
| CAS | 354126-20-8 |
| Formula | C26H22ClN3O3S2 |
| Molar Mass | 524.05 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Abdalhameed MM, et al. Structure-activity relationships of benzothiazole GPR35 antagonists. Bioorg Med Chem Lett. 2017;27(3):612-615. |
CID1231538
CAS: 354126-20-8 F: C26H22ClN3O3S2 W: 524.05
CID1231538, a benzothiazole analogue, is a potent GPR35 antagonist (IC50=0.55 μM). GPR35 is a G protein-coupled recepto
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.